NMS·Healthcare·$185M·#214 / 520 in Healthcare
TNXP Tonix Pharmaceuticals Holding C
50SPECULATIVE
CATEGORY BREAKDOWN
GROWTH48
QUALITY41
STABILITY91
VALUATION31
GOVERNANCE1
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+29.8%
48
> 50% strong
Gross Margin
Revenue retained after direct costs
49.3%
69
> 50% strong
Cash Runway
Months of cash at current burn rate
25 months
86
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.5%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
14.1x
31
< 3x strong
Rule of 40
Growth rate plus operating margin
-906
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.1%
1
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+106.5%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE TNXP WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when TNXP's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.